Clinical Trials Browser

Completed × INDUSTRY × acalabrutinib × Clear all

NCT02362035 2026-05-13

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Phase 2 Completed

48 enrolled 12 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02328014 2025-12-09

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Phase 1/2 Completed

40 enrolled 12 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04008706 2025-12-01

ASSURE

Phase 3 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04630756 2025-04-09

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Phase 1/2 Completed

40 enrolled 31 charts

Advanced Haematological Malignancies

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Phase 1 Completed

21 enrolled 11 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04930536 2024-11-22

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Phase 4 Completed

103 enrolled 10 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

Phase 1 Completed

COVID-19, Lymphoma, Mantle-Cell

NCT02211014 2020-07-31

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Phase 1 Completed

27 enrolled 13 charts

Multiple Myeloma

NCT02362048 2019-10-01

KEYNOTE144

Phase 2 Completed

77 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02537444 2019-09-25

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Phase 2 Completed

78 enrolled 10 charts

Ovarian Neoplasms

NCT02448303 2019-09-12

KEYNOTE166

Phase 2 Completed

74 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02454179 2019-09-12

KEYNOTE147

Phase 2 Completed

78 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

NCT02351739 2019-09-10

KEYNOTE143

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell